Ultragenyx Pharmaceutical (RARE) Retained Earnings (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Retained Earnings data on file, last reported at -$4.7 billion in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$4.7 billion, down 14.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.7 billion (down 14.83% YoY), and the FY2025 annual result was $1.0 million, up 100.03% from the prior year.
• Retained Earnings declined to -$4.7 billion in Q1 2026 per RARE's latest filing, from $1.0 million in the prior quarter.
• Over five years, Retained Earnings peaked at $1.0 million in Q4 2025 and troughed at -$4.7 billion in Q1 2026.
• A 5-year average of -$1.9 billion and a median of -$2.2 billion in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings slumped 3974958.93% in 2022, then jumped 100.03% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$2.8 billion in 2022, then soared by 100.02% to $647000.0 in 2023, then tumbled by 611691.96% to -$4.0 billion in 2024, then jumped by 100.03% to $1.0 million in 2025, then slumped by 471800.0% to -$4.7 billion in 2026.
• Business Quant data shows RARE's Retained Earnings at -$4.7 billion in Q1 2026, $1.0 million in Q4 2025, and -$4.4 billion in Q3 2025.